The U.S. Food and Drug Administration (FDA) has approved GSK’s Nucala (mepolizumab) for the treatment of chronic obstructive pulmonary disease. This approval expands Nucala’s indication as an add-on therapy for individuals with a specific form of COPD. https://www.coherentmarketinsights.com/news/fda-approves-gsks-nucala-to-treat-chronic-obstructive-pulmonary-disease-copd-1268